Saturday 17 October 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024. In the quarter to June 2026, revenue grew 466.4%, EPS grew 34.7%, free cash flow grew 9.97% and total debt fell 62.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

104.78 3.36 −3.11%

Follow KYMR

Alert me

Market cap: $9.0B
P/E: 0.0×
Fwd P/E: −20.8×
Dividend yield: —
F-score: 4/9
Altman Z: 23.22
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 172.50

Total sells 473.29

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	—	—	—	—	—	—
Sell	—	6	1	2	9	7	2	11	3	—	1	1

Insider Ownership 24.02%

Capital & Financial Ratios $m

Market Cap 8,990.00

Revenue 105.00

Net Income (299.60)

Free Cash Flow (237.96)

Net Debt (690.14)

Current Ratio 10.34

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (20.80)

P/S ratio 97.97

P/B ratio 6.82

Past 5Y EPS Growth —

This Y EPS Growth (4.51%)

Next Y EPS Growth (32.31%)

Next Y revenue growth 167.27%

Next 5Y EPS Growth (14.44%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 82.75%

10-year low 10-year high

P/B against its own 10 years 86.70%

10-year low 10-year high

EV/Sales against its own 10 years 82.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	375	489	848	691
Receivables	15	—	—	20
Inventory	—	—	—	—
Other	4	1	—	—
	405	510	871	737

	2023	2024	2025	Q'26
Payables	7	6	4	9
ST’ Debt	—	—	—	—
Other	1	0	0	0
	86	68	83	71

Compound Annual Growth %

	10y	5y	3y
Sales	—	2.87%	(5.74%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	40.96%	47.71%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	34	65	—	—	—
’25	22	11	3	3	39
’24	10	26	4	7	47
’23	9	17	5	48	79
’22	10	12	10	16	47
’21	19	19	20	15	73
’20	3	3	15	13	34

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(89)	(54)	—	—	—
’25	(79)	(60)	(27)	(67)	(233)
’24	(40)	(43)	(50)	(62)	(195)
’23	(44)	(35)	(32)	8	(103)
’22	(40)	(39)	(34)	(40)	(153)
’21	(23)	(31)	(37)	(38)	(129)
’20	(12)	(11)	132	(20)	88

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(89)	(55)	—	—	—
’25	(80)	(61)	(27)	(67)	(234)
’24	(47)	(48)	(50)	(63)	(207)
’23	(48)	(46)	(40)	(4)	(137)
’22	(41)	(40)	(36)	(40)	(156)
’21	(23)	(31)	(38)	(39)	(131)
’20	(13)	(15)	129	(22)	79

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.71)	(0.62)	—	—	—
’25	(0.82)	(0.95)	(0.94)	(0.97)	(3.69)
’24	(0.69)	(0.58)	(0.82)	(0.88)	(2.98)
’23	(0.70)	(0.67)	(0.90)	(0.25)	(2.52)
’22	(0.71)	(0.78)	(0.79)	(0.60)	(2.87)
’21	(0.29)	(0.55)	(0.56)	(0.66)	(2.09)
’20	(5.60)	(6.98)	(0.39)	(0.29)	(3.15)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	25.43	29.93	13.15	9.60	22.35	19.45	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	91.92	87.85	65.44	39.85	53.27	103.00
People
People	Employees	—	—	—	55	75	141	167	187	188	238
	Revenue/emp, $m	—	—	—	0.05	0.45	0.52	0.28	0.42	0.25	0.16
Income, $m
Income, $m	Revenue	—	—	—	3	34	73	47	79	47	39
	Gross margin, %	—	—	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(21)	(41)	(46)	(100)	(155)	(147)	(224)	(311)
	EBT margin, %	—	—	0.00	(1,405.79)	(133.96)	(137.60)	(330.60)	(186.99)	(475.57)	(794.04)
	Net income	—	0	(21)	(41)	(46)	(100)	(155)	(147)	(224)	(311)
	Depreciation	—	—	0	1	3	8	4	(2)	(7)	(1)
Per share, $
Per share, $	Revenue	—	—	0.00	1.73	1.96	1.52	0.87	1.35	0.63	0.46
	Earnings	—	—	(0.48)	(24.28)	(3.15)	(2.09)	(2.87)	(2.52)	(2.98)	(3.69)
	Cash flow	—	—	(0.40)	10.54	5.08	(2.69)	(2.84)	(1.76)	(2.59)	(2.76)
	Capex	—	—	0.00	(0.31)	(0.52)	(0.03)	(0.05)	(0.59)	(0.17)	(0.02)
	Free cash flow	—	—	(0.40)	10.23	4.56	(2.72)	(2.89)	(2.35)	(2.76)	(2.77)
	Book value	—	—	0.88	20.41	16.36	9.58	9.09	6.77	11.14	18.70
	Shares, m	—	—	45	2	17	48	54	58	75	84
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	31.61	41.83	28.61	18.83	64.14	167.66
	P/B	—	—	—	0.00	3.79	6.63	2.73	3.75	3.61	4.16
	EV/Sales	—	—	—	0.00	22.92	35.77	19.94	14.07	53.80	146.07
	EV/FCF	—	—	—	2.13	9.87	(19.96)	(5.99)	(8.05)	(12.21)	(24.44)
Cash, $m
Cash, $m	Operating cash flow	—	—	(18)	18	88	(129)	(153)	(103)	(195)	(233)
	Capex	—	—	(1)	(1)	(9)	(2)	(3)	(34)	(13)	(1)
	Free cash flow	—	—	(18)	17	79	(131)	(156)	(137)	(207)	(234)
Balance, $m
Balance, $m	Working capital	—	—	37	58	192	359	348	320	443	788
	Total debt	—	—	1	1	1	1	1	1	2	1
	Net debt	—	—	(41)	(91)	(296)	(441)	(406)	(374)	(487)	(847)
	Shareholders’ equity	—	—	39	35	284	460	490	395	836	1,580
Returns, %
Returns, %	ROA	—	—	(97.07)	(51.26)	(18.10)	(18.34)	(25.61)	(24.93)	(28.81)	(22.89)
	ROIC	—	—	0.00	0.00	0.00	(342.22)	(119.65)	(483.64)	(46.84)	(29.80)
	ROE	—	—	39.45	75.79	(52.17)	(26.96)	(32.60)	(33.21)	(36.38)	(25.78)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KRYS Krystal Biotech, Inc.	$9.8B	38.3×	38.6×	+24.14% (above 0%: growing)	+39.10% (above 0%: growing)	+40.14% (above 0%: growing)	94.60%	49.00%	Compare
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)
CAI Caris Life Sciences,�Inc.	$9.0B	81.3×	163×	+45.38% (above 0%: growing)	n/m	+8.47% (above 0%: growing)	68.10%	10.21%	Compare
CYTK Cytokinetics, Incorporated	$8.9B	— (loss-making)	— (loss-making)	−57.13% (below 0%: shrinking)	n/m	−24.02% (below 0%: shrinking)	80.46%	(625.95%)	Compare
PTGX Protagonist Therapeutics, Inc.	$8.8B	106×	25.0×	+3,749.17% (above 0%: growing)	n/m	+839.65% (above 0%: growing)	100.00%	74.37%	Compare
TGTX TG Therapeutics, Inc.	$8.6B	17.8×	29.4×	+70.27% (above 0%: growing)	−73.68% (below 0%: shrinking)	+427.05% (above 0%: growing)	82.86%	9.02%	Compare
AXSM Axsome Therapeutics, Inc.	$8.5B	— (loss-making)	— (loss-making)	+45.54% (above 0%: growing)	n/m	−2.98% (below 0%: shrinking)	93.79%	(22.73%)	Compare
ARWR Arrowhead Pharmaceuticals, Inc.	$8.3B	— (loss-making)	— (loss-making)	+171.02% (above 0%: growing)	n/m	−15.43% (below 0%: shrinking)	100.00%	(226.03%)	Compare
ABVX Abivax SA Sponsored ADR	$8.1B	— (loss-making)	—	—	n/m	−48.28% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$8.7B	59.8×	34.0×	+45.54%	—	+2.75%	88.33%	4.51%

All 614 Biotechnology stocks →

Kymera Therapeutics, Inc. (KYMR) key facts

Concern: Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
Kymera Therapeutics, Inc. (KYMR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KYMR traded at $104.78, a market capitalization of $9.0 billion.
Return on equity was −25.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 23.22 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.